MAEva program (mindfulness, acceptance, and commitment to values) for people treated for non‑metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, multicenter trial compares a nine‑week MAEva program to a nine‑week active discussion group in patients treated for non‑metastatic breast cancer. Participants are randomized to attend one weekly 1.5‑hour session for nine consecutive weeks of either MAEva (mindfulness, acceptance, and values‑based commitment exercises) or a discussion group. Quantitative measures of quality of life and psychological well‑being are collected at baseline and follow‑up to compare outcomes between groups. Eligible participants must be able to attend in‑person sessions and have no major psychiatric, cognitive, or sensory impairments that would prevent participation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with non-metastatic breast cancer,
* Patients who are able and willing to follow all study procedures in accordance with the protocol,
* Patients who have understood, signed, and dated the consent form,
* Patients who are affiliated with the social security system,
* Patients who are able to remain seated during the 1.5-hour sessions.

Exclusion Criteria:

* Patients with metastatic cancer,
* Presence of an acute psychiatric disorder: acute depression, unstable bipolar disorder, psychotic disorder (delusions, hallucinations), etc.
* Presence of recurrent uncontrolled panic attacks (particularly related to hypochondriacal concerns),
* Insufficient attentional resources for meditation: major attention, memory, or reasoning disorders,
* Presence of cognitive and neurocognitive disorders and deficits,
* Presence of deafness,
* Current participation in another mindfulness program,
* Persons deprived of their liberty or under guardianship (including curatorship),
* Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.

Where it's running

• Institut de Cancérologie de Lorraine
  Vandœuvre-lès-Nancy, France Recruiting

Study contacts

• Principal investigator: François Bourgognon, MD — Institut de Cancérologie de Lorraine
• Study coordinator: Jean-Louis Merlin, Professor
• Email: jl.merlin@nancy.unicancer.fr
• Phone: +33 3 83 59 84 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using cryotherapy and compression to prevent neuropathy in breast cancer patients

  This study is testing if using cold therapy and compression can help prevent nerve damage in women with breast cancer who are getting chemotherapy.

  Recruiting Centre Antoine Lacassagne · Nice · NCT06400849

• Reducing heart damage from chemotherapy in women with early breast cancer

  This study is testing if a drug called azeliragon can help protect the hearts of women with early breast cancer who are undergoing chemotherapy.

  Recruiting at 3 sites Phase 1/2 Georgetown University · Washington D.C., District of Columbia and 2 other locations · NCT05256745

• Targeted spinal radiation that spares adjacent vertebrae to treat pain from spinal bone metastases

  This project tests whether using smaller, targeted spinal radiation still relieves pain at 30 days for people with painful spinal bone metastases and whether telemonitoring can spot those who need extra care.

  Recruiting at 4 sites Institut de Cancérologie de Lorraine · Brest, Brest and 3 other locations · NCT06884332

• Digital self-hypnosis for managing hot flashes in breast cancer patients on hormone therapy

  This study tests if a guided digital self-hypnosis program can help women with breast cancer who are on hormone therapy reduce their hot flashes and improve their quality of life.

  Recruiting Institut de Cancérologie de Lorraine · Vandœuvre-lès-Nancy · NCT06552091

• Measuring circulating tumor DNA in patients with advanced upper aero-digestive tract cancer after radiotherapy

  This study is testing if measuring tumor DNA in the blood after radiation treatment can help predict how well patients with advanced throat and mouth cancer will do in the future.

  Recruiting at 7 sites Institut de Cancérologie de Lorraine · Caen, Caen and 6 other locations · NCT06479070

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.